Journal article
PRMT5 Inhibition Hits a Nerve (Sheath Tumor): A Targeted Strategy for MPNSTs
Clinical cancer research, Vol.31(22), pp.4620-4622
11/15/2025
DOI: 10.1158/1078-0432.CCR-25-2453
PMCID: PMC12481726
PMID: 40952693
Abstract
PRMT5 inhibitors represent a promising therapeutic approach for multiple cancers, but their clinical development is hindered by toxicity to normal cells. Synthetic lethality approaches using MTAP-cooperative PRMT5 inhibitors offer a compelling strategy that selectively targets cancer cells in nerve sheath sarcomas and other MTAP-deleted tumors.
Details
- Title: Subtitle
- PRMT5 Inhibition Hits a Nerve (Sheath Tumor): A Targeted Strategy for MPNSTs
- Creators
- Alexa P Sheehan - University of IowaAkshaya Warrier - University of IowaRebecca D Dodd - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Clinical cancer research, Vol.31(22), pp.4620-4622
- DOI
- 10.1158/1078-0432.CCR-25-2453
- PMID
- 40952693
- PMCID
- PMC12481726
- NLM abbreviation
- Clin Cancer Res
- ISSN
- 1078-0432
- eISSN
- 1557-3265
- Publisher
- AMER ASSOC CANCER RESEARCH
- Grant note
- National Institutes of Health (NIH): NS119322, P30 CA086862 Children's Tumor Foundation (CTF)U.S. Department of Defense (DOD): NF230081 Stead Family Scholar ProgramGilbert Family Foundation (GFF)
The authors are supported by the Department of Defense NF230081 (R.D. Dodd), NIH NS119322 (R.D. Dodd), Gilbert Family Foundation (R.D. Dodd), Stead Family Scholars Program (R.D. Dodd), Children's Tumor Foundation Young Investigator Award (A.P. Sheehan), NIH T32 grant CA078586 (A. Warrier), and NIH P30 CA086862 (R.D. Dodd).
- Language
- English
- Electronic publication date
- 09/15/2025
- Date published
- 11/15/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984964238202771
Metrics
4 Record Views